Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Unity Biotechnology stock | 4.78

Own Unity Biotechnology stock in just a few minutes.

Posted

Fact checked

Unity Biotechnology, Inc is a biotechnology business based in the US. Unity Biotechnology shares (UBX) are listed on the NASDAQ and all prices are listed in US Dollars. Unity Biotechnology employs 76 staff and has a market cap (total outstanding shares value) of USD$278.9 million.

How to buy shares in Unity Biotechnology

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Unity Biotechnology. Find the stock by name or ticker symbol: UBX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Unity Biotechnology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Unity Biotechnology, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Unity Biotechnology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Unity Biotechnology's share price?

Since the stock market crash in March caused by coronavirus, Unity Biotechnology's share price has had significant negative movement.

Its last market close was USD$4.78, which is 29.86% down on its pre-crash value of USD$6.815 and 3.46% up on the lowest point reached during the March crash when the shares fell as low as USD$4.62.

If you had bought USD$1,000 worth of Unity Biotechnology shares at the start of February 2020, those shares would have been worth USD$853.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$735.40.

Unity Biotechnology share price

Use our graph to track the performance of UBX stocks over time.

Unity Biotechnology shares at a glance

Information last updated 2020-11-25.
Latest market close USD$4.78
52-week range USD$2.72 - USD$12.46
50-day moving average USD$4.2544
200-day moving average USD$6.2189
Wall St. target price USD$5.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.973

Buy Unity Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Unity Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Unity Biotechnology price performance over time

Historical closes compared with the close of $4.78 from 2020-11-16

1 week (2020-11-15) N/A
1 month (2020-10-26) 16.02%
3 months (2020-08-22) N/A
6 months (2020-05-22) N/A
1 year (2019-11-22) N/A
2 years (2018-11-22) N/A
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Unity Biotechnology financials

Gross profit TTM USD$-70,957,000
Return on assets TTM -37.95%
Return on equity TTM -86.73%
Profit margin 0%
Book value $1.855
Market capitalisation USD$278.9 million

TTM: trailing 12 months

Shorting Unity Biotechnology shares

There are currently 2.7 million Unity Biotechnology shares held short by investors – that's known as Unity Biotechnology's "short interest". This figure is 10.2% down from 3.0 million last month.

There are a few different ways that this level of interest in shorting Unity Biotechnology shares can be evaluated.

Unity Biotechnology's "short interest ratio" (SIR)

Unity Biotechnology's "short interest ratio" (SIR) is the quantity of Unity Biotechnology shares currently shorted divided by the average quantity of Unity Biotechnology shares traded daily (recently around 663739.32038835). Unity Biotechnology's SIR currently stands at 4.12. In other words for every 100,000 Unity Biotechnology shares traded daily on the market, roughly 4120 shares are currently held short.

However Unity Biotechnology's short interest can also be evaluated against the total number of Unity Biotechnology shares, or, against the total number of tradable Unity Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Unity Biotechnology's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Unity Biotechnology shares in existence, roughly 50 shares are currently held short) or 0.0751% of the tradable shares (for every 100,000 tradable Unity Biotechnology shares, roughly 75 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Unity Biotechnology.

Find out more about how you can short Unity Biotechnology stock.

Unity Biotechnology share dividends

We're not expecting Unity Biotechnology to pay a dividend over the next 12 months.

Unity Biotechnology share price volatility

Over the last 12 months, Unity Biotechnology's shares have ranged in value from as little as $2.72 up to $12.46. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Unity Biotechnology's is -0.2106. This would suggest that Unity Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Unity Biotechnology has bucked the trend.

Unity Biotechnology overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site